Atomoxetine treatment of attention-deficit/hyperactivity disorder.
OBJECTIVE
To review the literature of the first nonstimulant approved for treatment of attention-deficit/hyperactivity disorder (ADHD).


METHODS
Primary literature and review articles were obtained through PubMed/MEDLINE (1966-February 2003).


METHODS
Literature evaluating atomoxetine in ADHD was selected. Animal data were excluded.


RESULTS
Stimulants are currently first-line therapy for ADHD. However, their use raises several concerns including the potential for abuse and adverse effects. Atomoxetine introduces a new therapeutic drug class, selective norepinephrine-reuptake inhibitors, for ADHD management. This additional treatment option offers potential advantages over current therapies.


CONCLUSIONS
Clinical trials demonstrate that atomoxetine is a safe and effective alternative for ADHD treatment in children and adults; however, its disadvantages may hinder it from becoming a first-line agent.
Eiland
Lea S
LS
Harrison School of Pharmacy, Auburn University, Huntsville, AL 35801, USA. eilanls@auburn.edu
Guest
Abby L
AL
D000284:Administration, Oral; D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D002214:Capsules; D004347:Drug Interactions; D006801:Humans; D011437:Propylamines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*
D018759:Adrenergic Uptake Inhibitors; D002214:Capsules; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride